Core Viewpoint - The company, Xingqi Eye Medicine, is experiencing positive market activity with a recent stock price increase and significant net inflow of funds, indicating strong investor interest and potential growth opportunities in the pediatric medication sector [1][3]. Group 1: Stock Performance - As of January 20, 2026, Xingqi Eye Medicine's stock closed at 81.38 yuan, reflecting a 1.81% increase with a turnover rate of 7.65% and a trading volume of 144,900 shares, resulting in a transaction value of 1.162 billion yuan [1]. Group 2: Company Strategy and Market Position - The company is considering its approach to national medical insurance policies and market conditions to make informed decisions regarding the inclusion of its products in insurance coverage [2]. - Currently, the company's main focus is on the domestic market, with ongoing discussions about potential international collaborations, particularly in the U.S. and EU markets, aiming for clinical trials and regulatory approvals by 2027 [2]. - The company plans to enhance market share through increased R&D investment, product structure optimization, production efficiency improvements, and market expansion efforts [2]. Group 3: Investor Sentiment and Fund Flow - On January 20, 2026, the net inflow of main funds into Xingqi Eye Medicine was 46.7078 million yuan, indicating strong institutional interest, while retail investors showed a net outflow of 46.9048 million yuan [3].